Androgen Receptor Pathway Inhibitors for Metastatic Hormone-Sensitive Prostate Cancer Outside of Randomized Controlled Trials: A Systematic Review and Meta-Analysis of Prognostic Factors in Real-World
3 hours ago
- #prognostic factors
- #real-world evidence
- #prostate cancer
- This systematic review and meta-analysis analyzed prognostic factors for overall survival (OS) and progression-free survival (PFS) in real-world patients with metastatic hormone-sensitive prostate cancer (mHSPC) treated with androgen deprivation therapy (ADT) plus androgen receptor pathway inhibitors (ARPI).
- The study included 16 retrospective observational studies, comprising 3773 patients, with multivariable-adjusted estimates used to minimize confounding.
- Poor performance status, low hemoglobin, high lactate dehydrogenase (LDH), and ISUP GG5 tumor grade were independently associated with worse OS.
- High extent of disease (EOD) was independently associated with worse PFS.
- Limitations include treatment selection bias, residual confounding, and heterogeneity in outcome definitions and prognostic factor measurements across studies.